Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection



Status:Recruiting
Conditions:Infectious Disease, Gastrointestinal, Hepatitis
Therapuetic Areas:Gastroenterology, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:10/20/2018
Start Date:October 10, 2018
End Date:April 12, 2022

Use our guide to learn which trials are right for you!

A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study

This study is being done to see if a minimal monitoring approach is effective and safe when
providing HCV treatment. The minimal monitoring approach will require fewer study visits and
lab tests with no medication refills. This study is trying to see whether taking an HCV
treatment with fewer clinic visits and laboratory tests can cure just as many people as the
standard approach that uses more visits and laboratory tests. The results of this study will
be compared with what has been observed in other studies using a standard approach.


Inclusion Criteria (Step 1):

- Ability and willingness of participant to provide informed consent.

- Active HCV infection confirmed by a detectable HCV RNA by PCR (HCV RNA >1000
international units (IU)/ml) within 35 days prior to study entry. HCV RNA must be
obtained by any FDA-approved test for quantifying HCV RNA at any local laboratory that
has a CLIA certification, its equivalent, or at any network-approved non-US laboratory
that operates in accordance with Good Clinical Laboratory Practices (GCLP) and
participates in appropriate external quality assurance programs. NOTE: HCV NRA can be
obtained at screening visit.

- HCV treatment naïve defined as not having been previously treated for HCV infection
with any medications approved for the treatment of HCV in any country.

- Liver disease stage defined as non-cirrhotic or compensated cirrhotic
(metric/diagnostic criteria used for fibrosis staging) within 35 days prior to study
entry as listed below:

A. FIB-4 <3.25 corresponding to no cirrhosis OR B. FIB-4 ≥3.25 AND Child-Turcotte-Pugh
(CTP) Score ≤6 indicating CTP Class A corresponding to compensated cirrhotic.

- HIV-1 infection status documented as either absent or present, as defined below:

Absence of HIV-1 infection, as documented by any licensed rapid HIV test or HIV-1 enzyme or
chemiluminescence immunoassay (E/CIA) test kit, within 60 days prior to entry.

OR

HIV-1 infection, documented by any licensed rapid HIV test or HIV-1 E/CIA test kit at any
time prior to entry and confirmed by a licensed Western blot or a second antibody test by a
method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1
RNA viral load.

NOTE: The term "licensed" refers to a US FDA-approved kit, which is recommended. For sites
that are unable to obtain an FDA-approved kit, a kit that has been certified or licensed by
an oversight body within the country and validated internally is acceptable.

WHO and CDC (US Centers for Disease Control and Prevention) guidelines mandate that
confirmation of the initial test result must use a test that is different from the one used
for the initial assessment. A reactive initial rapid test should be confirmed by either
another type of rapid assay or an E/CIA that is based on a different antigen preparation
and/or different test principle (e.g., indirect versus competitive), or a Western blot or a
plasma HIV-1 RNA viral load.

- For HIV co-infected participants, HIV-1 RNA obtained within 90 days prior to study
entry by any US laboratory that has a CLIA certification or its equivalent, or at any
network-approved non-US laboratory that operates in accordance with Good Clinical
Laboratory Practices (GCLP) and participates in appropriate external quality assurance
programs.

- HIV co-infected participants must satisfy one of the two criteria listed below:

A. If a participant is HIV-infected and is taking ART then, plasma HIV RNA <400 copies/mL
based on criteria listed in protocol AND current ARV regimen does not include efavirenz
(EFV) AND no exposure to EFV ≤14 days prior to study entry. Any absolute CD4+ count is
acceptable if this HIV RNA criterion is met.

NOTE: Any participant on an EFV containing ART regimen during the screening period must be
switched off EFV and have another regimen, excluding EFV, started at least 14 days prior to
study entry.

OR

B. If a participant is HIV-infected AND not taking ART, absolute CD4+ count must be >350
cells/µl.

- The following laboratory values obtained within 35 days prior to entry by any US
laboratory that has a CLIA certification or its equivalent, or at any network-approved
non-US laboratory that operates in accordance with Good Clinical Laboratory Practices
(GCLP) and participates in appropriate external quality assurance programs:

- Albumin >3.0 g/L

- Hemoglobin >8.0 g/dL for women; >9.0 g/dL for men

- Platelet count >50,000/mm3

- Calculated creatinine clearance (CrCl) using Cockcroft-Gault method >30 mL/min

- Aspartate aminotransferase (AST/SGOT) <10 times the upper limit of the normal
range (ULN)

- Alanine aminotransferase (ALT/SGPT) <10 times the ULN

- Total bilirubin <1.5 times the ULN for participants not on atazanavir (ATV) and
<3 times the ULN for participants on ATV

- International normalized ratio (INR) <1.5 times the ULN

- Female participants of reproductive potential (defined as women who have not been
post-menopausal for at least 24 consecutive months, i.e., who have had menses within
the preceding 24 months, or women who have not undergone surgical sterilization,
specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy)
must have a negative serum or urine pregnancy test within 48 hours prior to study
entry by any laboratory or clinic that has a CLIA certificate or its equivalent, or is
using a point-of-care (POC)/CLIA-waived test. The serum, urine or POC pregnancy test
must have a sensitivity of at least 25 mIU/mL.

- All participants of reproductive potential must agree not to participate in a
conception process (e.g., active attempt to become pregnant or to impregnate, sperm
donate, in vitro fertilization,) while on study treatment and for 6 weeks after
stopping protocol-specified medication.

- When participating in sexual activity that could lead to pregnancy, all participants
of reproductive potential must agree to use at least one reliable form of
contraceptive while receiving protocol-specified medication, and for 6 weeks after
stopping the medication. Such methods include: Condoms (either self or require their
partner to use one) with or without a spermicidal agent; Diaphragm or cervical cap
with or without spermicidal agent; Intrauterine device (IUD); Hormone-based
contraceptive; Tubal ligation.

NOTE: Providers and participants should be advised that not all contraceptive choices
listed above can prevent HIV transmission and that some may actually increase the risk of
HIV acquisition. Study participants who are sexually active with HIV-1 negative or unknown
HIV-1 serostatus partners should be advised that they need to consider effective strategies
for reducing the risk of HIV transmission, as well as meeting the requirement for effective
contraception during their participation in the study. Study participants should discuss
contraceptive choices and HIV risk reduction methods with their health care provider.

- Participants who are not of reproductive potential (women who have been
post-menopausal for at least 24 consecutive months or have undergone hysterectomy
and/or bilateral oophorectomy or salpingectomy or men who have documented azoospermia
or undergone vasectomy) are eligible without requiring the use of contraceptives.
Acceptable documentation of sterilization and menopause is specified below. Male
participants do not need to provide information on their female partner's reproductive
potential.

Written or oral documentation communicated by clinician or clinician's staff of one of the
following:

- Physician report/letter

- Operative report or other source documentation in the patient record (a laboratory
report of azoospermia is required to document successful vasectomy)

- Discharge summary

- Follicle stimulating hormone-release factor (FSH) measurement elevated into the
menopausal range as established by the reporting laboratory.

- Life expectancy >12 months, in the opinion of the site investigator.

- Willingness and ability to be contacted remotely via telephone, text message,
email, social media applications or any other modality.

Inclusion Criteria (Step 2):

- Completion of SVR evaluation visit in Step 1.

Exclusion Criteria (Step 1):

- Positive for the presence of hepatitis B virus (HBV) surface antigen (HBsAg).

- For cirrhotic participants, CTP score >6 corresponding to Class B or C.

- Breastfeeding or pregnancy.

- Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or
their formulation.

- Active drug or alcohol use or dependence and other conditions that, in the opinion of
the site investigator, would interfere with adherence to study requirements.

- Acute or serious illness requiring systemic treatment and/or hospitalization within 35
days prior to study entry.

- In HIV positive participants, presence of active or acute AIDS-defining opportunistic
infections within 35 days prior to study entry. NOTE: AIDS-defining opportunistic
infections as defined by the CDC found in the following document:
http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm

- Any history of hepatic decompensation including ascites, spontaneous bacterial
peritonitis, hepatic encephalopathy, hepatorenal syndrome, and/or bleeding esophageal
varices prior to study entry.

- Use of prohibited medications within the past 14 days prior to study entry.

There are no exclusion criteria for Step 2.
We found this trial at
21
sites
San Diego, California 92103
Principal Investigator: Constance A. Benson, MD
Phone: 619-543-3094
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Atlanta, Georgia 30308
Principal Investigator: Carlos Del Rio
Phone: 404-616-6313
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Thomas B Campbell, MD
Phone: 303-724-5931
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21205
Principal Investigator: Yukari C Manabe, MD
Phone: 410-955-8571
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Birmingham, Alabama 35294
Principal Investigator: Michael Saag, MD
Phone: 205-996-2373
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Rajesh Gandhi, MD
Phone: 617-724-0072
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Paul E. Sax, MD
Phone: 617-732-5635
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Beverly E Sha, MD
Phone: 312-942-2050
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45267
Principal Investigator: Carl Fichtenbaum, MD
Phone: 513-584-6383
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44106
Principal Investigator: Benigno Rodriguez, MD
Phone: 216-844-2546
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Susan Koletar, MD
Phone: 614-293-5856
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Greensboro, North Carolina 27401
Principal Investigator: Cornelius Van Dam, MD
Phone: 336-832-7888
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Roberto Arduino, MD
Phone: 713-500-6718
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Raphael Landovitz, MD
Phone: 310-557-3798
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90033
Principal Investigator: Fred Sattler, MD
Phone: 323-343-8283
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: Marshall J. Glesby, MD
Phone: 212-746-4166
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Pablo Tebas, MD
Phone: 215-349-8092
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Sharon Riddler, MD, MPH
Phone: 412-383-1675
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Rachel Presti, MD, PhD
Phone: 1-314-747-1098
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94110
Principal Investigator: Diane V. Havlir, MD
Phone: 415-476-4082
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Juan, 00935
Principal Investigator: Jorge Santana, MD
Phone: (787) 767-9192
?
mi
from
San Juan,
Click here to add this to my saved trials